CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Marker Therapeutics Inc (Old) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Marker Therapeutics Inc (Old)
4551 KENNEDY COMMERCE DR.
Phone: (713) 400-6400p:713 400-6400 HOUSTON, TX  77032  United States Fax: (302) 655-5049f:302 655-5049
Business Summary
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. It has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The Company is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYes----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200212/31/2001Yes----

Industries
SIC Code Description
7389 Business services, not elsewhere classified
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board N. DavidEansor 61 5/20/2022 10/17/2018
President, Chief Executive Officer, Director Peter L.Hoang 50 9/25/2017 9/25/2017
Chief Operating Officer, Chief Scientific Officer, Director Juan F.Vera 42 11/12/2021 10/17/2018
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 44 (As of 12/31/2020)
Outstanding Shares: 5,073,107 (As of 1/27/2023)
Shareholders: 101
Stock Exchange: OTC
Federal Tax Id: 880277072
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023